Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy

Blood

Volumn 127, Issue 20, 2016, Pages 2406-2410

  Gardner, Rebecca ^a,b   Wu, David ^a   Cherian, Sindhu ^a   Fang, Min ^a   Hanafi, Laïla Aïcha ^c   Finney, Olivia ^a   Smithers, Hannah ^a   Jensen, Michael C ^a,b   Riddell, Stanley R ^b,c   Maloney, David G ^b,c   Turtle, Cameron J ^b,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD4 ANTIGEN; CD64 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; INTERLEUKIN 6; MIXED LINEAGE LEUKEMIA PROTEIN; MYELOPEROXIDASE; ANTINEOPLASTIC AGENT; CD19 MOLECULE, HUMAN; CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR; HISTONE LYSINE METHYLTRANSFERASE; LYMPHOCYTE ANTIGEN RECEPTOR; MLL PROTEIN, HUMAN; ONCOPROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ANTIGEN EXPRESSION; ARTICLE; CELL THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOKINE RELEASE SYNDROME; FEMALE; FLOW CYTOMETRY; GENE REARRANGEMENT; HUMAN; MIDDLE AGED; PRIORITY JOURNAL; REMISSION; T LYMPHOCYTE; YOUNG ADULT; ACUTE MYELOID LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; BONE MARROW; CANCER STEM CELL; CASE REPORT; CELL CLONE; CHROMOSOME 11; GENE TRANSLOCATION; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; INFANT; LYMPHOCYTE DEPLETION; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENT DISEASE; SALVAGE THERAPY; T LYMPHOCYTE SUBPOPULATION; TUMOR ESCAPE;

ANTIGENS, CD19; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CHROMOSOMES, HUMAN, PAIR 11; CLONE CELLS; COMBINED MODALITY THERAPY; FEMALE; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; INFANT; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE DEPLETION; MIDDLE AGED; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NEOPLASTIC STEM CELLS; ONCOGENE PROTEINS, FUSION; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, ANTIGEN, T-CELL; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY; T-LYMPHOCYTE SUBSETS; TRANSLOCATION, GENETIC; TUMOR ESCAPE;

EID: 84971641150     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-08-665547     Document Type: Article

References (14)

1. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25.
2. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517-528.
3. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507-1517.
4. Sotillo E, Barrett DM, Black KL, et al. Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov. 2015;5(12):1282-1295.
5. Hilden JM, Dinndorf PA, Meerbaum SO, et al; Children's Oncology Group. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. Blood. 2006;108(2):441-451.
6. Moorman AV, Ensor HM, Richards SM, et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol. 2010;11(5):429-438.
7. Vey N, Thomas X, Picard C, et al; GET-LALA Group the Swiss Group for Clinical Cancer Research (SAKK). Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study. Leukemia. 2006;20(12):2155-2161.
8. Wang X, Chang WC, Wong CW, et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood. 2011;118(5):1255-1263.
9. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
10. Dorantes-Acosta E, Pelayo R. Lineage switching in acute leukemias: a consequence of stem cell plasticity. Bone Marrow Res. 2012;2012:406796.
11. Rossi JG, Bernasconi AR, Alonso CN, et al. Lineage switch in childhood acute leukemia: an unusual event with poor outcome. Am J Hematol. 2012;87(9):890-897.
12. Jacoby E, Nguyen SM, Welp KM, et al. Lineage switch as a relapse mechanism of pre-B acute lymphoblastic leukemia following CD19 CAR [abstract]. Blood. 2015;126(23). Abstract 2524.
13. Wei J, Wunderlich M, Fox C, et al. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. Cancer Cell. 2008;13(6):483-495.
14. Cohen A, Petsche D, Grunberger T, Freedman MH. Interleukin 6 induces myeloid differentiation of a human biphenotypic leukemic cell line. Leuk Res. 1992;16(8):751-760.